Company news

Clarity Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Paediatric neuroblastoma trial advances to cohort 3

August 23, 2022

Imaging trial in prostate cancer opens for recruitment

August 22, 2022

Application for quotation of securities - CU6

July 5, 2022

Governance & Trading Policy Update

June 8, 2022

IND Approval by US FDA for Phase II SAR-Bombesin trial

June 5, 2022

Notification regarding unquoted securities - CU6

June 1, 2022

Presentation Jefferies Biotech Summit

May 27, 2022

First patient treated in the prostate cancer imaging trial

April 21, 2022

Clarity Half Yearly Report

February 28, 2022

Half Year Accounts

February 28, 2022

Update on China Grand Pharmaceutical and Healthcare Holdings

February 27, 2022

First patient treated in cohort 2 neuroblastoma trial

February 24, 2022

US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA

February 6, 2022

Clarity receives $3.26 million R&D tax incentive refund

February 3, 2022

SARTATE Neuroblastoma trial advances to cohort 2

January 31, 2022

Managing Directors Presentation to Annual General Meeting

November 24, 2021

Quarterly Activity Report

November 18, 2021

Dosimetry Recruitment of theranostic prostate trial complete

November 9, 2021

Appendix 4C Cash Flow Report

October 26, 2021

Recruitment closed on C-BOBCAT SAR-Bombesin trial

October 18, 2021

App 4E Preliminary Final Report 30 June 2021

August 25, 2021

← Newer news releases

Decks

The 5 newest of 22 decks. Every deck is listed under its year.